This year zoomed by at Bina! We’ve grown tremendously and bagged several major accomplishments. Here are a couple of highlights from 2015:
Next-Generation Sequencing (NGS) is changing the way pharmaceutical companies develop drugs, perform patient stratification, and evaluate treatment efficacy. However, implementing a sound NGS strategy and maintaining a robust bioinformatics pipeline can be time consuming and costly. More importantly, presenting the data and insights gained from genomic analysis in a way that is consumable by translational scientists is essential.
Bina has taken home the top prize in genomic analysis at the 2015 Bio-IT World Conference & Expo! The Bina Genomic Management Solution (GMS) beat out other contenders in the category of Genetic Analysis with technology that enables translational and academic researchers to perform fast and scalable analysis to maximize the value of genomic data. The award was presented to Bina after a screening of 31 new products and 13 presentations by a panel of expert judges from academic and industry.
As NGS-driven drug discovery leads the charge in advancing human health, the need for an informatics infrastructure that can harness genomics information at scale while offering data management utility and global cloud security arises. At Bina, we solve the challenge by working hand-in-hand with leading pharmaceutical organizations to develop a comprehensive informatics management platform that drives data to insight.
Pleasanton, CA and Redwood City, CA April 21, 2015—Bina Technologies, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AstraZeneca (NYSE: AZN) today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution (GMS)1. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity.